Industry news · event 2026-02-02 · 3 min read
The administration-branded pharmacy channel launched in February 2026 listing Zepbound and Wegovy near $350 — a second door to manufacturer-tier pricing born from the 2025 pricing deals.
The administration-branded pharmacy channel launched in February 2026 listing Zepbound and Wegovy near $350 — a second door to manufacturer-tier pricing born from the 2025 pricing deals.
February 2026 added a third door to brand-tier GLP-1 pricing: TrumpRx, the administration-branded direct-purchase channel that grew out of the manufacturers' 2025 pricing agreements, launched with Zepbound and Wegovy listed in the ~$350 band.
Functionally, TrumpRx is a storefront to manufacturer-aligned self-pay pricing rather than a discounter — its GLP-1 numbers sit at or near LillyDirect's and NovoCare's own tiers ($299–$449 Zepbound; $349 Wegovy) — but it matters for reach and for the politics: the same negotiations produced the Medicare Part D opening that began covering Zepbound for qualifying patients months later at roughly a $50 copay.
For cash buyers, our guidance is unglamorous: the three brand channels (LillyDirect, NovoCare/retail savings card, TrumpRx) price within rounding of each other, so choose on convenience and refill logistics, and always run the insurance check first — a $25–$50 copay beats every storefront. Current verified figures for all three sit in the brand guide.